Switch in X-inactivation in a JAK2 V617F-negative case of polycythemia vera with two acquired X-autosome translocations

Leukemia Research

Volumn 31, Issue 7, 2007, Pages 1009-1014

  Manola, Kalliopi N ^a   Stavropoulou, Chryssa ^a   Georgakakos, Vasileios N ^a   Zoi, Katerina ^b   Fisfis, Markos ^c   Evmorfiadis, Ilias ^c   Zoi, Christine ^b   Pantelias, Gabriel E ^a   Stefanoudaki, Katy ^c   Sambani, Constantina ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

JAK2 V617F negative; Polycythemia vera; X autosome translocation; X inactivation

Indexed keywords

AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME INACTIVATION; CHROMOSOME REPLICATION; CHROMOSOME TRANSLOCATION; ERYTHROCYTOSIS; FEMALE; GENE SILENCING; HEMATOLOGIC DISEASE; HUMAN; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; X CHROMOSOME; X CHROMOSOME INACTIVATION;

AGED; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, X; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; POLYCYTHEMIA VERA; TRANSLOCATION, GENETIC; X CHROMOSOME INACTIVATION;

EID: 34249879025     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.11.014     Document Type: Article

References (20)

1. Pearson T.C., Messinezy M., Westwood N., Green A.R., Bench A.J., Green A.R., et al. A polycythemia vera update: diagnosis, pathobiology, and treatment. Am Soc Haematol Program (2000) 51-68
2. Cao M., Olsen R.J., and Zu Y. Polycythemia vera. New clinicopathologic perspectives. Arch Pathol Lab Med 130 (2006) 1126-1132
3. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 105 (2006) 4214-4222
4. Kalz-Fuller B., Sleegers E., Schwanitz G., and Schubert R. Characterization, phenotypic manifestations and X-inactivation pattern in 14 patients with X-autosome translocations. Clin Genet 55 (1999) 362-366
5. Sharp A.J., Spotswood H.T., Robinson D.O., Turner B.M., and Jakobs P.A. Molecular and cytogenetic analysis of the spreading of X inactivation in X;autosome translocations. Hum Mol Genet 11 (2002) 3145-3156
6. Popova B.C., Tada T., Takagi N., Brockdorff N., and Nesterova T.B. Attenuated spread of X-inactivation in an X-autosome translocation. PNAS 103 (2006) 7706-7711
7. Michaux L., Wlodarska I., Mecucci C., Hernandez J.M., Van Orsoven V., Michaux J.L., et al. Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in myelodysplastic syndromes. Cancer Genet Cytogenet 82 (1995) 17-22
8. Gray B.A., Confield D., Bent-Williams A., and Zori R.T. Translocation (X;20)(q13.1;q13.3) as a primary chromosomal finding in two patients with myelocytic disorders. Cancer Genet Cytogenet 141 (2003) 169-174
9. O'Reilly J., Crawford J., Uzaraga J., and Cannell P. Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder. Cancer Genet Cytogenet 158 (2005) 81-83
10. Reddy K.S., Richkind K., Ross M., and Seirra R. Translocation (X;20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders. Cancer Genet Cytogenet 157 (2005) 70-73
11. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
12. Baxter E.J., Scott L.M., Campbell P., East C., Fourouclas N., Swanton S., et al. Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
13. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A., Huntly B.J.P., et al. Mutation of JAK2 in the myeloprilipherative disorders: timing, clonality sydies, cytogenetic associations and role in leukemic transformation. Blood (2006) [Epub ahead of print]
14. Stavropoulou C., Mignon C., Delobel B., Moncla A., Depetris D., Croquette M.F., et al. Severe phenotype resulting from an active ring X chromosome in a female with a complex karyotype: characterization and replication study. J Med Genet 35 (1998) 0-6
15. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
16. Dierlamm J., Schilling G., Michaux L., Hinz K., Penas E.M., Seeger D., et al. Deletion of chromosome 15 represents a rare but recurrent chromosomal abnormality in myelocytic malignancies. Cancer Genet Cytogenet 144 (2003) 1-5
17. Saunders K., Williams Y., Aldouri M., Telford N., and Czepulkowski B. Deletion of chromosome arm 15q and hitherto unreported duplication of del(15q) in myeloid disorders. Cancer Genet Cytogenet 151 (2004) 146-151
18. McDonell N., Ramser J., Francis F., Vinet M.C., Rider S., Sudbrak R., et al. Characterization of a highly complex region in Xq13 and mapping of three isodicentric breakpoints associated with preleukemia. Genomics 64 (2000) 221-229
19. Vassiliou G.S., Campbell P.J., Li J., Roberts I., Swanton S., Huntly B.J.P., et al. An acquired translocation in JAK2 Val617 Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation. Haematologica 91 (2006) 1100-1104
20. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790